Product Detail  

Brief Introduction of KLOW80:

Klow80 is a comprehensive research blend combining four well-characterized peptides commonly investigated in laboratory models of systemic inflammation, tissue regeneration, and epithelial recovery. This formulation supports multifactorial in vitro studies involving cellular signaling and repair mechanisms.

Purity: >99% (or refer to the Certificate of Analysis)

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Shelf Life: >2 years if stored properly

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

TB500 is a synthetic peptide fragment of human , a potent actin-regulating protein. It features a purity of ≥98% (HPLC) and is supplied as a sterile, white lyophilized powder. Primarily designed for research use, it promotes cell migration, angiogenesis, collagen deposition, and tissue repair by binding to actin and modulating cellular repair pathways. It is water-soluble after reconstitution, stable at -20°C, and packaged in sealed vials for laboratory investigation.

Production：
Manufactured via solid-phase peptide synthesis (SPPS), followed by purification and lyophilization to obtain the final product.

NOTE: This product was prepared by chemical synthesis. Used only for research. Not for human use.

Tirzepatide (M-ounjaro) is a novel medication indicated as an adjunct to diet and exercise in the treatment of patients with type 2 diabetes mellitus. Tirzepatide is a dual receptor agonist, acting on glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) to lower blood glucose levels.
  Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 agonist that has been studied recently as a treatment for patients with noncirrhotic NASH (SYNERGY-NASH, NCT04166773) given its association with significant weight loss and improvement in features of metabolic syndrome in diabetes trials.

 Retatrutide     (LY3437943) acetate is a triple agonist peptide for the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R).

Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643, and 0.775 nM, respectively. It exhibits activity on mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191, and 0.794 nM, respectively.

In vivo, Retatrutide (LY3437943) acetate engages with GCGR and enhances glucose tolerance in an ipGTT by acting through GIP or GLP-1 receptors. Activation via the glucagon receptor by Retatrutide acetate leads to significant weight reduction and increased energy expenditure. Retatrutide acetate can be utilized in research related to obesity.